Breaking News Instant updates and real-time market news.

TRVN

Trevena

$6.03

0.11 (1.86%)

13:53
10/19/16
10/19
13:53
10/19/16
13:53

Meet Trevena: CEO Gowen expects new clinical trial data in Q1

In an exclusive interview with The Fly, Trevena's (TRVN) CEO Maxine Gowen discussed the company's primary drug candidate Oliceridine, or TRV130, and its ongoing Phase 3 studies: "We are still expecting to share the top line data from both [Oliceridine] APOLLO studies in the first quarter of 2017 as we have guided. Our goal for Oliceridine is a labeled indication for the management of moderate to severe acute pain. So that means any moderate to severe pain when an IV medicine is appropriate and that's regardless of what causes the pain. According to FDA, you can get a broad label like this or this can be supported by demonstrating efficacy in both the hard tissue and the soft tissue pain in the case study. So that's why our Phase 3 program includes bunionectomy, which is a hard tissue model of bone surgery, and an abdominoplasty trial, which is a soft tissue model. We use both of these models in the Phase 2 trials and from that we generated the very compelling data around Oliceridine's efficacy as well as safety and tolerability compared to morphine. So with those two [APOLLO] pivotal trials as well as the multi procedure ATHENA study, which is a trial we're doing, we believe that we'll have sufficient data to support that broad label indication without the need to do any further trials." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

  • 22

    Oct

  • 13

    Dec

TRVN Trevena
$6.03

0.11 (1.86%)

03/02/16
WBTH
03/02/16
INITIATION
Target $18
WBTH
Buy
Trevena initiated with a Buy at WallachBeth
WallachBeth analyst Caroline Palomeque started Trevena with a Buy rating and $18 price target. The company's lead candidate Oliceridine for post-operative acute pain may offer patients a treatment option with comparable analgesic efficacy, a faster onset of action and a more favorable safety profile than morphine, Palomeque tells investors in a research note.
03/02/16
03/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chemical Financial (CHFC) initiated with a Strong Buy at Raymond James by analyst David Long, who believes its pending accretive merger with Talmer Bancorp (TLMR) will provide the base for a more profitable company with strengthened growth prospects. 2. Infinity Pharmaceuticals (INFI) initiated with an Outperform at FBR Capital, with analyst Christopher James saying that duvelisib has the potential to be a first-in-class treatment for specific types of blood cancers. 3. Trevena (TRVN) initiated with a Buy at WallachBeth by analyst Caroline Palomeque, who said Oliceridine may offer patients a treatment option with comparable analgesic efficiency, a faster onset of action and a more favorable safety profile than morphine. 4. Aduro Biotech (ADRO) initiated with an Outperform at FBR Capital. 5. LKQ Corp. (LKQ) initiated with a Buy at Sterne Agee CRT. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/16
FBRC
03/29/16
INITIATION
Target $16
FBRC
Outperform
Trevena initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Trevena with an Outperform rating and $16 price target.
05/17/16
ROTH
05/17/16
NO CHANGE
Target $14.5
ROTH
Buy
Roth Capital remains a buyer of Trevena
Roth Capital analyst Michael Higgins reiterates a Buy rating and $14.50 price target on Trevena's shares. The analyst says the company announced that its TRV027 failed in Phase 2 and will be discontinuing the program. However, given the relative risk of development between its oliceridine and its TRV027, Higgins is not making any changes to his financial models. Trevena is "well-capitalized," with cash sufficient to fund operations for two years, the analyst tells investors in a research note, adding that he sees the company's shares as being at an "attractive entry point."

TODAY'S FREE FLY STORIES

AMGN

Amgen

$173.14

-0.15 (-0.09%)

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Hot Stocks
Amgen says Repatha gets EU approval for new single-dose option »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 09

    Mar

  • 17

    Mar

  • 21

    Mar

  • 19

    Jul

LNTH

Lantheus

, GE

General Electric

$30.57

0.195 (0.64%)

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Hot Stocks
Lantheus, GE Healthcare sign term sheet for flurpiridaz development »

Lantheus Medical Imaging,…

LNTH

Lantheus

GE

General Electric

$30.57

0.195 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 26

    Apr

GBT

Global Blood Therapeutics

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Syndicate
Global Blood Therapeutics files to sell $75M in common stock »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

, CI

Cigna

$146.52

2.96 (2.06%)

15:57
02/21/17
02/21
15:57
02/21/17
15:57
Hot Stocks
LifeNet says Dermacell receives coverage from Cigna »

Cigna (CI) now covers…

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

CI

Cigna

$146.52

2.96 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 28

    Feb

PBYI

Puma Biotechnology

$40.25

2.9 (7.76%)

15:56
02/21/17
02/21
15:56
02/21/17
15:56
Options
Puma Biotechnology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Jul

SODA

SodaStream

$47.14

-0.53 (-1.11%)

15:54
02/21/17
02/21
15:54
02/21/17
15:54
Hot Stocks
Teleios Capital lowers stake in SodaStream to 4.5% »

Teleios Capital has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$27.00

0.2 (0.75%)

15:48
02/21/17
02/21
15:48
02/21/17
15:48
Hot Stocks
Matrix Partners China lowers stake in Momo to 12.6% from 15.4% »

On September 23, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

BMY

Bristol-Myers

$53.55

-1.04 (-1.91%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Hot Stocks
Breaking Hot Stocks news story on Bristol-Myers »

Bristol-Myers up 2.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

BMY

Bristol-Myers

$53.54

-1.05 (-1.92%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Periodicals
Carl Icahn takes stake in Bristol-Myers, WSJ reports »

Icahn sees value in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

DEPO

Depomed

$16.47

-0.38 (-2.26%)

15:35
02/21/17
02/21
15:35
02/21/17
15:35
Options
Depomed options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CSCO

Cisco

$33.74

0.14 (0.42%)

15:32
02/21/17
02/21
15:32
02/21/17
15:32
Conference/Events
Cisco to host service provider tech talk »

Cisco SVP Kanouff hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

EFA

iShares MSCI EAFE Index Fund

$60.65

0.15 (0.25%)

15:31
02/21/17
02/21
15:31
02/21/17
15:31
Options
Defensive option play opened in the iShares MSCI EAFE Fund »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$16.96

0.1 (0.59%)

15:26
02/21/17
02/21
15:26
02/21/17
15:26
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$8.85

0.55 (6.63%)

15:25
02/21/17
02/21
15:25
02/21/17
15:25
Conference/Events
Cantor Fitzgerald health/pharma analysts hold analyst/industry conference call »

Analysts, along with Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

$NSD

NASDAQ Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENT

Global Eagle

$6.22

-0.01 (-0.16%)

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Downgrade
Global Eagle rating change  »

Global Eagle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

, AMGN

Amgen

$173.29

1.18 (0.69%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Hot Stocks
Bass group fails to prove Aralez patent claims unpatentable »

The Coalition For…

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

AMGN

Amgen

$173.29

1.18 (0.69%)

BIIB

Biogen

$288.94

-1.19 (-0.41%)

ABBV

AbbVie

$61.66

-0.1147 (-0.19%)

JNJ

Johnson & Johnson

$119.49

0.63 (0.53%)

SHPG

Shire

$181.08

2.38 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 26

    Jun

  • 19

    Jul

HCLP

Hi-Crush Partners

$21.58

0.275 (1.29%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Options
Hi Crush options imply 9.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TWTR

Twitter

$16.42

-0.2 (-1.20%)

15:18
02/21/17
02/21
15:18
02/21/17
15:18
Hot Stocks
Twitter head of entertainment talent resigns »

Lara Cohen, head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

KRP

Kimbell Royalty Partners

$19.90

0.15 (0.76%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Hot Stocks
Breaking Hot Stocks news story on Kimbell Royalty Partners »

Rivercrest Royalties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$36.07

-0.09 (-0.25%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Options
Goodyear Tire put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$20.11

-0.06 (-0.30%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Conference/Events
Barrick Gold to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

, HON

Honeywell

$124.79

0.2317 (0.19%)

15:15
02/21/17
02/21
15:15
02/21/17
15:15
Hot Stocks
Marathon Patent unit files patent infringement suits against Honeywell, Somfy »

Marathon Patent Group…

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

HON

Honeywell

$124.79

0.2317 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 01

    Mar

  • 29

    Mar

  • 24

    Apr

15:15
02/21/17
02/21
15:15
02/21/17
15:15
General news
Breaking General news story  »

San Francisco Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.